Trial intelligence / Profile preview

2 versus 4 cycles of neoadjuvant CAPOX for low/intermediate-risk rectal cancer

ChiCTR2100047327Phase 4Recruiting

Sponsor
West China Hospital of Sichuan University
Start
Jul 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of capecitabine and oxaliplatin in rectal cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological tumor regression grade. Started Jul 2021; status: recruiting.

02

Drugs

capecitabineoxaliplatin
03

Conditions

rectal cancer

Beyond the preview

Go deeper on ChiCTR2100047327.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100047327.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call